HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 99/3/1515    most recent 00598.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Hickman, J. A. Articles by Jonas, E. A. Search for Related Content PubMed PubMed Citation Articles by Hickman, J. A. Articles by Jonas, E. A.

Bcl-xL Inhibitor ABT-737 Reveals a Dual Role for Bcl-xL in Synaptic Transmission

¹Institut de Recherches Servier, Croissy sur Seine, France; ²Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Public Health, Baltimore, Maryland; and ³Departments of Pharmacology and ⁴Internal Medicine, Yale University, New Haven, Connecticut

Submitted 25 May 2007; accepted in final form 19 December 2007

A role for BCL-xL in regulating neuronal activity is suggested by its dramatic effects on synaptic function and mitochondrial channel activity. When recombinant BCL-xL is injected into the giant presynaptic terminal of squid stellate ganglion or applied directly to mitochondrial outer membranes within the living terminal, it potentiates synaptic transmission acutely, and it produces mitochondrial channel activity. The squid, however, is a genetically intractable model, making it difficult to apply genetic tools in squid to explore the role of endogenous BCL-xL in synaptic function. Therefore the small molecule inhibitor ABT-737, a mimetic of the BH3-only protein BAD, binding to the BH3-binding domain pocket, was tested in squid, revealing a dual role for BCL-xL. ABT-737 slowed recovery of synaptic responses after repetitive synaptic activity, indicating that endogenous BCL-xL is necessary for timely recovery of rapidly firing synapses. Unexpectedly, however, ABT-737 also protected neurons from hypoxia-induced synaptic rundown and from increased permeability of the mitochondrial outer membrane during hypoxia. This implies that endogenous BCL-xL or a modified form of BCL-xL, such as the N-truncated, proteolytic, pro-apoptotic cleavage product, N BCL-xL, contributes to injurious responses of the hypoxic synapse. To determine if ABT-737 is also an inhibitor of N BCL-xL, recombinant N BCL-xL protein was injected into the synapse. ABT-737 potently inhibited synaptic rundown induced by recombinant N BCL-xL. These observations support the possibility that endogenous proteolysis or a functionally equivalent modification of BCL-xL is responsible for the deleterious effects of hypoxia on synaptic activity.

This article has been cited by other articles:

				S. B. Berman, Y.-b. Chen, B. Qi, J. M. McCaffery, E. B. Rucker III, S. Goebbels, K.-A. Nave, B. A. Arnold, E. A. Jonas, F. J. Pineda, et al. Bcl-xL increases mitochondrial fission, fusion, and biomass in neurons J. Cell Biol., March 9, 2009; 184(5): 707 - 719. [Abstract] [Full Text] [PDF]

				S. M. O'Brien, D. F. Claxton, M. Crump, S. Faderl, T. Kipps, M. J. Keating, J. Viallet, and B. D. Cheson Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia Blood, January 8, 2009; 113(2): 299 - 305. [Abstract] [Full Text] [PDF]

				S. O'Brien New Agents in the Treatment of CLL Hematology, January 1, 2008; 2008(1): 457 - 464. [Abstract] [Full Text] [PDF]